瑞银发表报告，列出最具潜力超市场预期收益((Buy rated HK listed stocks with highest UBSe earnings upside above consensus estimate)的港股买入名单：股份│瑞银与同业对企业今明两年综合盈测差异康希诺生物(06185.HK) +0.440 (+1.168%) 沽空 $48.41万; 比率 2.359% │97%石药集团(01093.HK) +0.240 (+3.187%) 沽空 $2.50亿; 比率 32.849% │60%三生制药(01530.HK) -0.260 (-0.924%) 沽空 $7.63千万; 比率 16.928% │42%科济药业-B(02171.HK) -0.300 (-1.734%) 沽空 $2.69百万; 比率 11.545% │42%上石化(00338.HK) -0.010 (-0.746%) 沽空 $50.92万; 比率 11.208% │37%越秀地产(00123.HK) +0.100 (+2.410%) 沽空 $2.86千万; 比率 34.459% │35%金风科技(02208.HK) -0.110 (-0.865%) 沽空 $7.39百万; 比率 8.236% │33%科伦博泰生物-B(06990.HK) -14.400 (-3.376%) 沽空 $9.18千万; 比率 22.204% │27%中信建投证券(06066.HK) -0.140 (-1.127%) 沽空 $2.29千万; 比率 17.526% │26%恒瑞医药(01276.HK) +0.850 (+1.144%) 沽空 $5.64千万; 比率 19.304% │25%海丰国际(01308.HK) -0.560 (-2.009%) 沽空 $3.38千万; 比率 25.386% │23%药明康德(02359.HK) -0.300 (-0.287%) 沽空 $8.86千万; 比率 17.642% │22%(wl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-12-10 16:25。)